Stimulated protein degradation to promote mitochondrial function and neuronal survival

Targeted protein degradation is a promising modality to treat cancer or inflammation, but whether it can provide a similar benefit for disorders caused by pervasive protein dysregulation is unclear.

By Chandrasekhar, McMinimy, Manford +7Science (New York, N.Y.)Oct 29, 2026

Score████░░░░░░4.4

VerdictWorth a reader's time today.

Read the original

Abstract

Targeted protein degradation is a promising modality to treat cancer or inflammation, but whether it can provide a similar benefit for disorders caused by pervasive protein dysregulation is unclear. We describe stimulated protein degradation (SPD) as a strategy that leverages agonists of stress-responsive E3 ubiquitin ligases to simultaneously eliminate multiple pathogenic factors. Specifically, we show that activators of the reductive stress response E3 CUL2FEM1B boost degradation of multiple physiological substrates to improve mitochondrial import and electron transport chain assembly. In this manner, CUL2FEM1B agonists preserve mitochondrial function and neuronal survival in models of neurodegenerative COX deficiency syndrome and Friedreich's ataxia. By activating E3 ligases that evolved to safeguard cellular integrity, SPD expands the use of compound-induced protein degradation to complex pathologies of high unmet need.

Srividya Chandrasekhar, Rachael McMinimy, Andrew G Manford, Eddie Wehri, Christine L Gee, Caitlyn Miller, Baris Bingol, John Kuriyan, Julia Schaletzky, Michael Rapé

The editor's rubric

Heuristic review

Leverage3 / 5: A method or resource many groups across the field will adopt within a year.; 24% of this desk’s rubric
Magnitude3 / 5: Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem.; 16% of this desk’s rubric
Evidence3 / 5: Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data.; 20% of this desk’s rubric
Novelty3 / 5: A genuinely new approach to an open problem.; 20% of this desk’s rubric
Trajectory2 / 5: Some room to improve with obvious engineering.; 10% of this desk’s rubric
Stakes3 / 5: Meaningful benefit to many people within a few years.; 10% of this desk’s rubric

Dimension	Level	Weight	What that level means
Leverage	███░░3/5	24%	A method or resource many groups across the field will adopt within a year.
Magnitude	███░░3/5	16%	Large gain: roughly 2x, or a clear new state of the art on a hard, unsaturated problem.
Evidence	███░░3/5	20%	Solid: multiple benchmarks or cohorts, ablations, fair baselines, released code or data.
Novelty	███░░3/5	20%	A genuinely new approach to an open problem.
Trajectory	██░░░2/5	10%	Some room to improve with obvious engineering.
Stakes	███░░3/5	10%	Meaningful benefit to many people within a few years.

Editor’s rationale

Heuristic triage from title and abstract text only, not a reading of the paper. Cues found: method (we report); stakes (genetic disease, mortality, major disease).

How the score was computed

rank-2026-10-18

Score████░░░░░░4.4

Score = 10 × (75% × adjusted merit / 10 + 15% × attention + 10% × freshness)

Desks place stronger verdicts first, then use this score to order work within the same verdict.

Merit: 5.8 / 10; Weighted rubric, evidence-gated.
Adjusted merit: 4.7 / 10; Shrunk toward the desk prior by editor confidence (38%).
Attention: 4%; Citations, upvotes, points, mentions.
Freshness: 80%; Half-life decay since publication.

Citations1 (reference 20, via openalex, Oct 31, 2026, 05:48 UTC)

The record

Reviewed by heuristic-v10 on Oct 31, 2026, 05:48 UTC. Paper type: method.
Categories: Journal Article, Neurons, Mitochondria, Humans, Cullin Proteins, Carrier Proteins, Cell Cycle Proteins, Cell Survival, HEK293 Cells, Proteolysis
BRIEF, No.8 in the Biology edition of October 31, 2026.